{"id":"trofosfamide-idarubicin-etoposide","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Hair loss"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-15%","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Trofosfamide works by attaching an alkyl group to the DNA molecule, which interferes with DNA replication and transcription. Idarubicin intercalates DNA, which prevents the replication of DNA and ultimately leads to cell death. Etoposide inhibits topoisomerase II, an enzyme that unwinds DNA during replication, which prevents DNA replication and leads to cell death.","oneSentence":"Trofosfamide is an alkylating agent that interferes with DNA replication, idarubicin is an anthracycline antibiotic that intercalates DNA, and etoposide is a topoisomerase inhibitor that prevents DNA replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:15.237Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia"},{"name":"Small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT00876031","phase":"PHASE3","title":"Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2009-07-01","conditions":"Soft Tissue Sarcoma","enrollment":195}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"trofosfamide, idarubicin, etoposide","genericName":"trofosfamide, idarubicin, etoposide","companyName":"University Hospital Tuebingen","companyId":"university-hospital-tuebingen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trofosfamide is an alkylating agent that interferes with DNA replication, idarubicin is an anthracycline antibiotic that intercalates DNA, and etoposide is a topoisomerase inhibitor that prevents DNA replication. Used for Acute myeloid leukemia, Small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}